[Expression of AIB1 protein in gynecological tumors].
OBJECTIVE
To investigate the expression of AIB1 (amplified in breast cancer 1) protein in gynecological cancers, and to analyze the role and clinical significance of AIB1 protein in carcinogenesis and development of gynecological cancers.


METHODS
By immunohistochemical method SP, we examined the AIB1 expression levels and relative clinico-pathological features in 10 normal cervical tissues and 18 cervical cancers; 18 normal endometrium tissues and 46 endometrium carcinoma; 19 normal ovarian tissues and 74 epithelial ovarian cancers.


RESULTS
The expression rate of AIB1 protein in cervical carcinoma wasn't higher than that in normal cervical tissues, but AIB1 expression was correlated with lymph node involvement. The positive expressions of AIB1 in carcinoma of endometrium and ovarian cancers were significantly higher than those in normal tissues. In carcinoma of endometrium, the rate of AIB1 expression in poorly-differentiated cancer was obviously higher than it in well-differentiated cancer. There was an inverse relationship between AIB1 expression levels and histological tumor grades (P = 0.02). It showed the tendency forward that the AIB1 expression increased with the progress of clinical stages (P = 0.006).


CONCLUSIONS
The overexpression of AIB1 may play a role in the carcinogenesis and development of gynecological cancers, especially ovarian cancers.
Han
Xiao-Yan
XY
Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
Zhang
Xue-Mei
XM
Chen
Yue
Y
Yang
Kai-Xuan
KX
Qie
Ming-Rong
MR
D002454:Cell Differentiation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005833:Genital Neoplasms, Female / Q000235:genetics* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D056921:Nuclear Receptor Coactivator 3 / Q000378:metabolism*
C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3